Detecting the MET Exon 14 Skipping Mutations in NSCLC
Willemina R. Geurts-Giele, PhD, discusses 2 approaches used to detect the MET exon 14 skipping mutation in patients with non-small cell lung cancer.
Willemina R. Geurts-Giele, PhD, University Medical Center, Rotterdam, The Netherlands, discusses 2 approaches used to detect theMETexon 14 skipping mutation in patients with non-small cell lung cancer (NSCLC).
Clinicians can use either RNA or DNA, Geurts-Giele says. With RNA, a simple polymerase chain reaction is used because it is the same event, which is very easy. However, the downside is that patients with NSCLC do not have as much material.
DNA analyses are routinely done in pathology departments, while the use of RNA is still evolving in labs. In her analysis, Guerts-Giele used DNA analysis to determine theMETexon 14 skipping mutation because they regularly run the analysis on their patient’s materials.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
